Zymedi’s ZMA001 Granted Orphan Drug Designation by FDA

Zymedi’s first-in-class antibody treatment ZMA001, currently in development for pulmonary arterial hypertension (PAH), has been designated as an Orphan Drug by the U.S. Food and Drug Administration (FDA).

Pulmonary arterial hypertension is an inflammatory vascular disease characterized by the remodeling and narrowing of pulmonary arterioles due to various causes. Currently, most treatments involve vasodilators, which only alleviate symptoms without providing a cure. Due to the diverse causes of PAH, there is a critical need for the development of targeted therapies.

According to Zymedi, ZMA001 is a human monoclonal antibody that blocks the infiltration of inflammation-inducing macrophages into the lungs, thereby fundamentally inhibiting the symptoms of PAH from the early stages. In preclinical development, animal model studies demonstrated superior efficacy compared to existing drugs.

Notably, ZMA001 has shown a synergistic effect when used in conjunction with existing medications, positioning it as a potential game-changer in PAH treatment, where innovative drugs are urgently needed.

Zymedi’s CTO Nam Hoon Kwon stated, “With the Orphan Drug designation for ZMA001, we hope to provide a valuable treatment option for PAH patients in need of new therapies.”

Kwon further emphasized, “The FDA’s Orphan Drug designation offers various benefits, including tax credits for clinical trial costs, seven years of market exclusivity upon approval, and assistance with the drug development process, which are particularly advantageous for startup companies with limited resources and time constraints, aiding in clinical progression and commercial success.”

Phase 1a clinical trial for ZMA001 began at the NIH Clinical Center in January, involving healthy adult participants. This initial phase focuses on evaluating the safety and tolerability of the drug in humans. Preliminary results from these trials will help determine the appropriate dosages and identify any potential side effects, paving the way for subsequent phases of clinical testing.